Dr. Andrew Walker is a senior, highly experienced health economist and HTA expert with over two decades of direct experience in national health technology assessment processes, including 12 years at the Scottish Medicines Consortium (SMC) as a decision-maker (voting committee member) and Head of the Health Economics Review team, including extensive involvement with NICE. He holds a PhD in health economics (University of Nottingham). His career focuses on evaluating new medicines across all therapeutic areas, advising on evidence generation, economic modelling, pricing, and reimbursement strategies to optimize HTA outcomes in the UK and beyond.

From 2002 to 2014 at SMC, Dr. Walker helped establish the health economics review framework, co-authored submission guidance for companies, created the health economics checklist, led approximately 150 reviews of new medicines, interrogated dossiers, liaised with clinicians, and briefed committees. He continued as a quality checker post-2014. He served as a consultant to the University of Aberdeen Evidence Review Group (2018–2022), critiquing cost-effectiveness evidence, writing ERG report sections, handling clarifications, and participating in Appraisal Committee meetings for multiple Single Technology Appraisals. Concurrently (2018–2022), he provided Early Scientific Advice as an external expert selected by NICE, reviewing briefing books and advising companies on HTA requirements. Since 2015, as Founder, Owner, and Director of Salus Alba (an HTA consultancy), he has advised over 100 global, European, and country-level pharmaceutical and biotech companies on pipeline HTA risks, investment decisions in therapy areas, Phase 3 trial design (including economic data collection), pricing strategies, Global Value Dossier reviews, UK submission plans (with mock committee simulations), and training on HTA/economic evaluation. He remains actively engaged with current NICE/SMC methods, regularly studies guidance, attends committee meetings, and shares insights via LinkedIn (500+ connections, 400+ endorsements) and think pieces on topics like QALY modifiers, severity adjustments, and real-world evidence. Dr. Walker combines insider knowledge of UK HTA bodies with practical consulting to guide innovative therapies toward successful reimbursement and patient access.